20,50 €
3,09 % heute
L&S, 6. Oktober, 18:10 Uhr
ISIN
US6951271005
Symbol
PCRX
Berichte

Pacira Pharmaceuticals, Inc. Aktie News

Neutral
GlobeNewsWire
3 Tage alt
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on October 2, 2025 to 15 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducem...
Neutral
GlobeNewsWire
etwa ein Monat alt
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material in...
Neutral
The Motley Fool
2 Monate alt
Pacira BioSciences (PCRX -1.74%) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% (non-GAAP), while revenue (GAAP) came in at $181.1 million, missing GAAP revenue expectations by 1.1%. Compar...
Neutral
Seeking Alpha
2 Monate alt
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Brendan P. Teehan - Chief Commercial Officer Frank D.
Neutral
GlobeNewsWire
2 Monate alt
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth --
Neutral
GlobeNewsWire
2 Monate alt
BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025.
Neutral
PRNewsWire
3 Monate alt
SAN DIEGO , July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at mail@sharehol...
Neutral
GlobeNewsWire
3 Monate alt
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducem...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen